Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR

NCT02178397 is registered in ClinicalTrials.gov with Centre Francois Baclesse as lead sponsor.

NCT NCT02178397
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02178397 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR
Lead sponsor
Centre Francois Baclesse
Phase
Phase 3
Overall status
Terminated
Start date
June 30, 2014
Completion date
September 30, 2015
Enrollment
6 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc patients with egfr activating mutation